© 2020 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
MPNs | Clinical
Low-Dose Ruxolitinib Improves Splenomegaly and Symptoms in Myelofibrosis
November 25, 2020
Low-dose ruxolitinib appears effective as treatment of patients with myelofibrosis, improving splenomegaly and symptoms with a daily dose ≤ 10 mg.
JUMP Post Hoc Analyses Pinpoint Predictive Factors for Response and Symptom Improvement in Myelofibrosis
November 25, 2020
Investigators conducted post hoc analyses of the phase 3 JUMP clinical trial to determine how clinical characteristics correlate with response to therapy in patients with myelofibrosis.
Pacritinib Demonstrates Potential to Fill Unmet Need in Myelofibrosis
November 21, 2020
John O. Mascarenhas, MD, discusses pacritinib for patients with myelofibrosis and thrombocytopenia.
The Role of JAK Inhibitors Continues to Evolve to Improve Outcomes in Myelofibrosis
November 10, 2020
In an interview with Targeted Oncology, John O. Mascarenhas, MD, discussed the evolving role of JAK inhibitors for the treatment of patients with myelofibrosis, including new agents under evaluation in randomized studies and potential combination strategies that may also improve outcomes.
JAK Inhibitors Appear Hopeful for Transplant-Eligible MPN Patients in Retrospective Data
October 15, 2020
Uday R. Popat, MD, discusses the role of JAK inhibitors in patients with myeloproliferative neoplasms.
New Therapies in Development for Myelofibrosis
October 15, 2020
Building on the transformative impetus from the first FDA-approved JAK 1/2 inhibitor, ruxolitinib, in the clinical landscape of myeloproliferative neoplasms, we are entering a new era of multiple JAK inhibitors and other diverse classes of drugs in rapid clinical development.
Rolling NDA Planned for Submission to FDA for Pacritinib in Myelofibrosis With Severe Thrombocytopenia
October 14, 2020
A rolling submission of a New Drug Application has been initiated for pacritinib, seeking FDA approval for the drug as treatment of patients with myelofibrosis with severe thrombocytopenia.
Treatment Options Expand Beyond JAK Inhibition for Patients With Myelofibrosis
October 11, 2020
During the National Comprehensive Cancer Network 2020 Virtual Congress: Hematologic Malignancies, Aaron Gerds, MD, MS, reviewed the current treatment landscape for patients with myelofibrosis and what’s to come for the treatment of this patient population as clinical trials continue to advance the field.
New Drug Application Planned for Submission to FDA for Pacritinib in Myelofibrosis
September 30, 2020
A New Drug Application for pacritinib is planned to be submitted for potential accelerated approval from the FDA for the treatment of patients with myelofibrosis and severe thrombocytopenia.
Genomic Testing Should Be Standard in Myelofibrosis at Diagnosis, Says Rampal
September 22, 2020
Raajit K. Rampal, MD, PhD, discussed the role of genomics in the treatment landscape of myelofibrosis and the remaining challenges that need to be addressed in order to use this information more effectively to treat patients and improve outcomes.